DOJ Closes FCPA Inquiry Against Dr. Reddy's Without Enforcement Action
RDY sits 16% above its 52-week low of $12.26.
Summary
Dr. Reddy's Laboratories announced the U.S. Department of Justice has closed its Foreign Corrupt Practices Act inquiry without recommending enforcement action, fully resolving a significant legal overhang.
Key Events · Legal and Risk Events · RDY
-
DOJ Closes FCPA Inquiry
The U.S. Department of Justice, Criminal Division, Fraud Section, has closed its inquiry under the Foreign Corrupt Practices Act (FCPA) against Dr. Reddy's Laboratories.
-
No Enforcement Action Recommended
Based on available information, the Department of Justice has not recommended any enforcement action against the company.
-
Resolution of Legal Overhang
This follows the SEC's conclusion of its related investigation on February 24, 2026, without recommending enforcement action, effectively resolving a multi-year legal risk concerning alleged improper payments.
Analysis · RDY · Life Sciences
Dr. Reddy's Laboratories has announced the definitive closure of the U.S. Department of Justice's inquiry under the Foreign Corrupt Practices Act (FCPA) without any recommendation for enforcement action. This follows the SEC's similar conclusion reported on February 24, 2026. The resolution of this multi-year investigation by both major U.S. regulatory bodies removes a significant legal and financial overhang that has weighed on the company, eliminating the risk of substantial fines and reputational damage associated with potential FCPA violations. This development provides clarity and de-risks the investment thesis.
At the time of this filing, RDY was trading at $14.27 on NYSE in the Life Sciences sector, with a market capitalization of approximately $11.9B. The 52-week trading range was $12.26 to $16.17. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.